DAWN (Day One Biopharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

DAWN (Day One Biopharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$158M

Net Income (TTM)-$107M

EPS (TTM)-$1.04

Free Cash Flow (TTM)-$108M

Gross Margin89.1%

Op. Margin-80.8%

Net Margin-67.8%

FCF Margin-68.0%

P/S Ratio (TTM)14.0x

P/E Ratio (TTM)—

YoY Rev Growth+20.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	-$89K	-$46M
Q2 23	$0	-$92K	-$49M
Q3 23	$0	-$99K	-$51M
Q4 23	$0	-$103K	-$60M
Q1 24	$0	-$116K	-$67M
Q2 24	$8M	$7M	-$115M
Q3 24	$94M	$92M	$30M
Q4 24	$29M	$26M	-$65M
Q1 25	$31M	$28M	-$41M
Q2 25	$34M	$30M	-$35M
Q3 25	$40M	$35M	-$24M
Q4 25	$54M	$48M	-$27M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	269.6x	—
Q3 24	21.7x	—
Q4 24	16.8x	—
Q1 25	13.6x	—
Q2 25	11.8x	—
Q3 25	16.5x	—
Q4 25	14.0x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$26M
Q2 23	-$42M	-$43M
Q3 23	-$37M	-$40M
Q4 23	-$41M	-$41M
Q1 24	-$50M	-$50M
Q2 24	-$49M	-$66M
Q3 24	$51M	-$5M
Q4 24	-$30M	-$31M
Q1 25	-$59M	-$63M
Q2 25	-$25M	-$21M
Q3 25	-$6M	-$6M
Q4 25	-$14M	-$18M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$26K
Q2 23	$149K
Q3 23	$3M
Q4 23	$8K
Q1 24	$0
Q2 24	$17M
Q3 24	$56M
Q4 24	$1M
Q1 25	$4M
Q2 25	$3M
Q3 25	$0
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+65.3%
Q2 23	—	+34.1%
Q3 23	—	+29.6%
Q4 23	—	+39.2%
Q1 24	—	+45.6%
Q2 24	—	+149.7%
Q3 24	—	+24.7%
Q4 24	—	+58.8%
Q1 25	—	+7.6%
Q2 25	+313.9%	-44.0%
Q3 25	-57.6%	-0.1%
Q4 25	+83.9%	-14.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	—
Q2 23	$9M	—
Q3 23	$10M	—
Q4 23	$11M	—
Q1 24	$13M	—
Q2 24	$13M	159.1%
Q3 24	$12M	12.3%
Q4 24	$11M	37.8%
Q1 25	$13M	41.8%
Q2 25	$11M	32.1%
Q3 25	$10M	24.0%
Q4 25	$11M	20.6%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$28M	$18M
Q2 23	$32M	$17M
Q3 23	$33M	$18M
Q4 23	$37M	$22M
Q1 24	$40M	$26M
Q2 24	$92M	$30M
Q3 24	$34M	$29M
Q4 24	$62M	$30M
Q1 25	$40M	$29M
Q2 25	$36M	$29M
Q3 25	$31M	$28M
Q4 25	$41M	$34M

Revenue Segments

Quarter	Product	License
Q2 24	$8M	—
Q3 24	$20M	$74M
Q4 24	$29M	$253K
Q1 25	$31M	$258K
Q2 25	$34M	$346K
Q3 25	$39M	$1M
Q4 25	$53M	$884K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$49M	$269M	$318M
Q2 23	$189M	$254M	$443M
Q3 23	$241M	$164M	$406M
Q4 23	$231M	$136M	$366M
Q1 24	$270M	$48M	$318M
Q2 24	$240M	$122M	$362M
Q3 24	$423M	$136M	$558M
Q4 24	$125M	$407M	$532M
Q1 25	$33M	$440M	$473M
Q2 25	$36M	$417M	$453M
Q3 25	$43M	$408M	$452M
Q4 25	$197M	$244M	$441M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	72M	-2.0%
Q2 23	75M	+4.2%
Q3 23	86M	+14.7%
Q4 23	87M	+1.5%
Q1 24	87M	-0.6%
Q2 24	87M	+0.5%
Q3 24	97M	+11.3%
Q4 24	94M	-3.4%
Q1 25	103M	+9.7%
Q2 25	103M	+0.3%
Q3 25	103M	+0.3%
Q4 25	103M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	55
FY 22	$0	121
FY 23	$0	155
FY 24	$725K	181
FY 25	$791	200K